利格列汀

利格列汀（CAS 668270-12-0）的公开数据库记录，列此仅供独立核对。

物理形态与操作说明

• White to yellow solid; also reported as a crystalline solid
• Soluble in methanol; sparingly soluble in ethanol; very slightly soluble in isopropanol, alcohol
• Stable if stored as directed; avoid strong oxidizing agents
• Thermal decomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides.
• Slightly hygroscopic
• A 5mg oral dose of linagliptin results in >80% inhibition of dipeptidyl peptidase 4 (DPP-4) for ≥24 hours. Inhibition of DPP-4 increases the concentration of glucagon-like peptide 1 (GLP-1), leading to decreased glycosylated hemoglobin and fasting plasma glucose.

公开数据库收录的理化数据

这个物质在各数据库里的编号

数据库记载的用途

• Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.
• Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. Linagliptin has been linked to rare instances of clinically apparent liver injury.
• Breast Feeding; Lactation; Milk, Human; Hypoglycemic Agents; Incretins; Dipeptidyl-Peptidase IV Inhibitors; DPP-4 Inhibitors
• Linagliptin; METformin Hydrochloride
• Tradjenta tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. /Included in US product label/
• There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking Tradjenta. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue Tradjenta and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Tradjenta.

它在各数据库里的别名

Linagliptin; 668270-12-0; Tradjenta; BI-1356; BI 1356; Trazenta; Trajenta; BI-1356-BS; linagliptine; Linagliptina; BS 1356 BS; BI1356; 3X29ZEJ4R2; BI-1356BS; BI 1356 BS; BS-1356-BS

计算机算出的分子描述符

数据库摘要

Linagliptin · CAS 668270-12-0 · C25H28N8O2. UNII 3X29ZEJ4R2. 熔点: 190-196; 熔点: 202 °C; 溶解度: <1 mg/mL.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。